Market revenue in 2023 | USD 28.6 million |
Market revenue in 2030 | USD 67.3 million |
Growth rate | 13% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 45.1% in 2023. Horizon Databook has segmented the Saudi Arabia hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia's hereditary angioedema therapeutics market is estimated to exhibit significant growth over the forecast period, owing to rapid launch of new products in the region and increasing number of government initiatives.
In recent years, Saudi Arabia has witnessed an increase in research activities that can help improve access to effective treatment. However, the lack of awareness among patients regarding the accessibility of advanced therapies may hamper market growth.
Initiatives undertaken by key players to enhance and improve awareness are anticipated to accelerate market growth in the coming years. The local presence of organizations, such as HAE International, focusing on building a network of healthcare professionals to help provide faster and more efficient treatment is further propelling the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account